Response Genetics, Roche Ink Cancer Test Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics has signed a deal with Roche Diagnostics to support the development of a cancer assay.

The Los Angeles-based firm said today that it had licensed to Roche non-exclusive rights to use its PCR analysis technology to assess human epidermal growth factor type 2 gene expression. A test that can accurately measure HER2 expression could assist physicians with treatment decisions for patients with certain cancers in tissues such as breast.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.